milliporesigma videos

81. Optimize The Formulation Of A Monoclonal Antibody 12/11/2019

    You have a molecule of interest and need an effective formulation to maximize stability and minimize aggregation. As with all formulations, it is essential that the buffers and excipients ensure stability of the drug substance, be compatible with each other and meet regulatory requirements. An emerging biotech company sought our help in developing a formulation for a monoclonal antibody. Learn how we have delivered an optimized formulation for this customer in three months.

82. Scale Your Process Directly From 3L To 2,000L Blindfolded 12/11/2019

    In the biotech industry, you need to move quickly and use resources efficiently to advance a drug candidate into the clinic and ultimately onto the market. Being able to quickly produce a batch at the right time and at the right size is essential to support development and get to the finish line faster. We developed a strategy to enable a direct, efficient and robust tech transfer of a monoclonal antibody production process from a 3L bioreactor to 2000L without the need for any intermediate volumes.

83. Increase The Titer Of A Difficult To Express Molecule 12/11/2019

    What happens if you have a promising molecule but can’t engineer a cell line to deliver the titer needed to support clinical development?  A low process titer may render the molecule, such as an antibody, too costly to manufacture and unsuitable for continued investment. Learn how our client achieved a nearly 4-fold titer increase.

84. How To Generate A High-Producing Cell Line In Fast-Track Mode 12/11/2019

    Cell line development processes can be quite time consuming and labor intensive. When our clients have a very challenging timeline, we can begin process development in parallel with cell line development, further accelerating timelines. What are the risks and how do you minimize risk?

85. Accelerate Identification Of High-Producing Cell Lines 12/11/2019

    When companies are putting in place an upstream process, a critical step is generation of a cell line expressing the protein of interest. Unfortunately, the search for the best-producing clone is often compared with looking for a needle in a haystack. Watch our video to learn about our mini-pool approach and the value of automated systems to efficiently create, screen and isolate high producing clones with reduced costs.

86. Assuring Viral Safety: Better, Faster, Virus Production 11/14/2019

    Viral safety is tricky when your product is a virus. Learn about the strategies that can help prevent, detect and remove the “bad” viruses from your virus production processes.

87. Flexible Manufacturing: Better, Faster Virus Production 11/7/2019

    The global vaccine market is growing due to population growth, emerging pathogens and pandemics. The increased demand has led to new vaccines, manufacturing facility projects and increasing investments. Using flexible manufacturing strategies can help meet this growing vaccine demand.

88. Biotherapy Characterization: Cell-Based Assays 7/17/2019

    MilliporeSigma Senior Scientist Agata Burzawa, MSc, explains how we can provide you with rich data sets to help you understand your complex biotherapy faster. Using limited volumes of samples for testing, our scientists employ leading technologies that integrate cytokine release monitoring with immunophenotyping of cells within the same sample.

89. Biotherapy Characterization: Binding Assays 7/17/2019

    MilliporeSigma Senior Scientist Helen Hsu, Ph.D. describes how, with our custom binding assays, and supported with our comprehensive off-the-shelf Fc gamma receptor binding assays, we can help you optimize your mAb production, from clone development through upstream and downstream processes.

90. Explore What's Next: Product Characterization 7/17/2019

    Newer, high-resolution analytical techniques help answer questions regarding product heterogeneity and drug functions, and help assess for product-related aggregates and impurities.